Hu, Zishuo Ian <br/><br/>
A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer.  [electronic resource] 

 -  Cancer medicine  09 2019 
 - 5148-5157 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>2045-7634 
<br/><br/><label>Standard No.: </label>10.1002/cam4.2425  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Albumins--administration & dosage<br/>Antibodies, Monoclonal--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Biomarkers<br/>Deoxycytidine--administration & dosage<br/>Disease Management<br/>Female<br/>Humans<br/>Kaplan-Meier Estimate<br/>Male<br/>Middle Aged<br/>Molecular Targeted Therapy<br/>Paclitaxel--administration & dosage<br/>Pancreatic Neoplasms--drug therapy<br/>Prognosis<br/>Receptor, Notch2--antagonists & inhibitors<br/>Receptor, Notch3--antagonists & inhibitors<br/>Treatment Outcome<br/>Gemcitabine